Ascentage Pharma declares first patient dosed in APG-2575 trial
Category: #health  By Nikita Chaurasia  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ascentage Pharma declares first patient dosed in APG-2575 trial

APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Ascentage Pharma has reportedly announced that it has dosed the first patient in a phase I medical study of APG-2575, a new Bcl-2 selective inhibitor, for treating hematologic malignancies in China. The company also has a continuing multi-center phase I APG-2575 dose-escalation trial as a single agent in Australia and the United States. APG-2575 is anticipated to potentially be the first Bcl-2 inhibitor made in China.

For the record, APG-2575 is an innovative, orally managed Bcl-2 selective inhibitor. It is created to heal hematologic malignancies through selective blocking Bcl-2 to recreate the regular apoptosis process in cancer cells.

Reportedly, the founding member of the Bcl-2 family proteins is Bcl-2. The Bcl-2 family proteins are most prominent for their significant roles in regulating apoptosis by the development of heterodimers through pro-apoptotic proteins (BAD, BIM and many others). It is complicated to create a drug which affects Bcl-2 family protein due to the hydrophobic and very large Bcl-2 protein interfaces. The promoted Bcl-2 inhibitor venetoclax/ABT-199 accepted by the U.S. FDA in April 2016 has legalized the medical basis for more targeted drug development. APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Sources claimed that the Phase I trial is created to evaluate the tolerance and safety of APG-2575 in patients enduring hematologic malignancies. The trial is also designed to check the recommended Phase II dose (RP2D) or maximal tolerated dose (MTD) of APG-2575. Patients with acute Non-Hodgkin's Lymphoma (NHL) and Acute Myelogenous Leukemia (AML) have been Included in this trial. Presently, the first enrolled patient has been medicated during the initial stage of dose-escalation.

Ascentage Pharma has reportedly released numerous preclinical research outcomes of APG-2575 during the annual meeting of 2019 American Association for Cancer Research (AACR). The results have shown the potential in combination therapy.

Source credit:

https://www.prnewswire.com/news-releases/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical-trial-of-apg-2575-in-china-as-the-first-china-made-bcl-2-inhibitor-300884516.html

https://www.tullahomanews.com/news/business/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical/article_8c4cdc27-db63-59f8-9ce9-dd301581f9fc.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...